Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Duraprep

Research Leaders

6 sponsors active, led by National Institute of Neurological Disorders and Stroke (NINDS)

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03393819Not ApplicableCompleted

Efficacy of Surgical Skin Preparation Solutions in Hip Arthroplasty Surgery

NCT01089712Completed

Management Practices and the Risk of Infection Following Cardiac Surgery

Showing all 2 trials

Research Network

Common Treatments

  • Duraprep1
  • Chloraprep1

Active Sponsors

  • National Institute of Neurological Disorders and Stroke (NINDS)1
  • Thunder Bay Regional Health Sciences Centre1
  • National Heart, Lung, and Blood Institute (NHLBI)1
  • Canadian Institutes of Health Research (CIHR)1
  • Icahn School of Medicine at Mount Sinai1

Top Investigators

Related Conditions

  • Postoperative Wound Infection1
  • Infections Nosocomial1
  • Arthroplasty Hip Replacement1
  • Cardiac Surgery1
  • Management Practices1

Activity Timeline